참고문헌
- Papageorgiou KI, Mathew RG, Kaniorou-Larai MG, Yiakoumetis A. Pyoderma gangrenosum in ulcerative colitis: considerations for an early diagnosis. BMJ 2005;331:1323-4. https://doi.org/10.1136/bmj.331.7528.1323
- Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33:787-802. https://doi.org/10.1016/j.rdc.2007.07.016
- Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005;81:580-5. https://doi.org/10.1136/pgmj.2004.031633
- Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23:1008-17. https://doi.org/10.1111/j.1468-3083.2009.03199.x
- Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis 1998;4:142-8. https://doi.org/10.1002/ibd.3780040209
- Fernandez A, Velasco A, Prieto V, Canueto J, Alvarez A, Rodriguez A. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis. Am J Gastroenterol 2008;103:2951-2. https://doi.org/10.1111/j.1572-0241.2008.02094_14.x
- Molnar T, Farkas K, Nagy F, Wittmann T. Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report. Inflamm Bowel Dis 2008;14:1752-3. https://doi.org/10.1002/ibd.20485
- Ermis F, Ozdil S, Akyüz F, Pinarbasi B, Mungan Z. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis. Inflamm Bowel Dis 2008;14:1611-3. https://doi.org/10.1002/ibd.20481
- Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. https://doi.org/10.1053/j.gastro.2007.05.029
- Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34:395-409. https://doi.org/10.1016/S0190-9622(96)90428-4
- Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55:505-9. https://doi.org/10.1136/gut.2005.074815
- Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease: a cohort study of 2402 patients. Medicine 2008;87:281-93. https://doi.org/10.1097/MD.0b013e318187cc9c
- Wollina U. Pyoderma gangrenosum--a review. Orphanet J Rare Dis 2007;2:19. https://doi.org/10.1186/1750-1172-2-19
- Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149-58. https://doi.org/10.2165/00128071-200203030-00002
- Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003;32:967-95. https://doi.org/10.1016/S0889-8553(03)00046-3